Agilent Posts Double-Digit Falloff in Q4 Revenues, Delays Varian Deal to 2010 | GenomeWeb

By Tony Fong

Agilent Technologies today reported a 9 percent slide in its Bio-Analytical Measurement segment amid a 21 percent drop in overall revenues for its fiscal fourth quarter, to close out "an extraordinarily difficult year," according to the firm's president and chief executive.

The company also said that its planned $1.5 billion acquisition of Varian is now expected to close in early 2010 instead of the end of 2009 as previously planned.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.